Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 07, 2024 07:30 ET | Source: Legend Biotech USA Inc.

Legend Biotech to Host Investor Event During the 66th American Society of Hematology (ASH) Annual Meeting and Exposition

SOMERSET, N.J., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a live webcast event for investors on Sunday,...
November 05, 2024 09:10 ET | Source: Legend Biotech USA Inc.

Legend Biotech to Unveil Minimal Residual Disease Data from Landmark CARTITUDE-4 Trial in Multiple Myeloma

New data will showcase significantly increased and sustained minimal residual disease (MRD) negativity rates, reinforcing the potential of CARVYKTI to transform outcomes in refractory multiple myeloma...
November 04, 2024 07:30 ET | Source: Legend Biotech USA Inc.

Legend Biotech Appoints Alan Bash as President of CARVYKTI®

SOMERSET, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced the appointment of Alan Bash as the...
October 24, 2024 08:00 ET | Source: Legend Biotech USA Inc.

Legend Biotech to Host Investor Conference Call on Third Quarter 2024 Results

SOMERSET, N.J., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET...
October 03, 2024 07:30 ET | Source: Legend Biotech USA Inc.

Legend Biotech to Establish New, State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia

SOMERSET, N.J., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), announced it is establishing a new, state-of-the-art research and development (R&D)...
September 27, 2024 16:35 ET | Source: Legend Biotech USA Inc.

CARVYKTI® is the First and Only Cell Therapy to Significantly Extend Overall Survival Compared to Standard of Care in Patients with Multiple Myeloma as Early as Second Line

Landmark CARTITUDE-4 study results show CARVYKTI® reduced the risk of death by 45 percent after three-year follow-upLate-breaking data featured in an oral presentation at the 21st International...
August 20, 2024 08:00 ET | Source: Legend Biotech USA Inc.

Legend Biotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

SOMERSET, N.J., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that Ying Huang, Ph.D., the company’s...
August 09, 2024 07:00 ET | Source: Legend Biotech USA Inc.

Legend Biotech Reports Second Quarter 2024 Results and Recent Highlights

CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $186 millionMHRA and Health Canada approved CARVYKTI® in earlier lines of treatment for adult patients with...
August 08, 2024 16:05 ET | Source: Legend Biotech USA Inc.

Legend Biotech Appoints Peter Salovey, Ph.D., to its Board of Directors

SOMERSET, N.J., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced the appointment of Peter Salovey,...
July 26, 2024 07:00 ET | Source: Legend Biotech USA Inc.

Legend Biotech Announces Preliminary Results for the Six-Months Ended June 30, 2024

SOMERSET, N.J., July 26, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced preliminary, unaudited financial...